Akums Drugs and Pharmaceuticals Limited IPO
- IPO Date30 Jul, 2024 to 01 Aug, 2024
- Listing Date06 Aug, 2024
- Face Value₹2 per share
- Issue Price₹646 to ₹679 per share
- Lot Size22 Shares
- Minimum Investment₹14,938
- Listing AtBSE, NSE
- Total Issue Size2,73,45,162 Shares
(aggregating up to ₹1856.74 Cr) - Fresh Issue1,00,14,727 Shares
(aggregating up to ₹680.00 Cr)
- Offer for Sale1,73,30,435 Shares
(aggregating up to ₹1176.74 Cr) - Issue TypeBook Built Issue IPO
- Share holding pre issue14,73,56,280
- Shareholding post issue15,73,71,007
IPO Dates
Closing Date
01 Aug, 2024
Initiation of Refunds
05 Aug, 2024
Listing Date
06 Aug, 2024
30 Jul, 2024
Opening Date
02 Aug, 2024
Basis of Allotment
05 Aug, 2024
Credit of Shares
Akums Drugs and Pharmaceuticals Limited Lot Size
Investors can bid for a minimum of 22 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Max) | 13 | 286 | ₹1,94,194 |
| S-HNI (Max) | 66 | 1452 | ₹9,85,908 |
| Retail (Min) | 1 | 22 | ₹14,938 |
| B-HNI (Min) | 67 | 1474 | ₹10,00,846 |
| S-HNI (Min) | 14 | 308 | ₹2,09,132 |
Akums Drugs and Pharmaceuticals Limited Promoter Holding
Sanjeev Jain, Sandeep Jain, and Akums Master Trust are the company's promoters.
| Pre Issue Share Holding | Post Issue Share Holding |
|---|---|
| 84.94% | - |
Akums Drugs and Pharmaceuticals Limited COMPANY INFORMATION
Akums Drugs and Pharmaceuticals IPO is a book built issue of Rs 1,856.74 crores. The issue is a combination of fresh issue of 1 crore shares aggregating to Rs 680.00 crores and offer for sale of 1.73 crore shares aggregating to Rs 1,176.74 crores. Akums Drugs and Pharmaceuticals IPO opens for subscription on July 30, 2024 and closes on August 1, 2024. The allotment for the Akums Drugs and Pharmaceuticals IPO is expected to be finalized on Friday, August 2, 2024. Akums Drugs and Pharmaceuticals IPO will list on BSE, NSE with tentative listing date fixed as Tuesday, August 6, 2024. Akums Drugs and Pharmaceuticals IPO price band is set at ₹646 to ₹679 per share. The minimum lot size for an application is 22 Shares. The minimum amount of investment required by retail investors is ₹14,938. The minimum lot size investment for sNII is 14 lots (308 shares), amounting to ₹209,132, and for bNII, it is 67 lots (1,474 shares), amounting to ₹1,000,846. ICICI Securities Limited, Axis Bank Limited, Citigroup Global Markets India Private Limited and Ambit Private Limited are the book running lead managers of the Akums Drugs and Pharmaceuticals IPO, while Link Intime India Private Ltd is the registrar for the issue. Refer to Akums Drugs and Pharmaceuticals IPO RHP for detailed information.
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
The company primarily provides end-to-end solutions for product development and manufacturing as well as research and development (R&D) of formulations, preparation and submission of regulatory dossiers in the Indian and global markets and other testing services. The company is also engaged in the manufacture and sale of branded drugs and active pharmaceutical ingredients (APIs).
As a CDMO, the company manufactures a wide range of dosage forms including tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections and gummy bears, to name a few.
The company has produced a total of 4,025 commercialized formulations in over 60 dosage forms. In the financial year 2023, the company manufactured formulations for 26 of the top 30 pharmaceutical companies in India in terms of revenue. For its CDMO business, the company operates 10 manufacturing units with a cumulative production capacity of 49.21 billion units annually (as of September 30, 2023).
The company plans to expand its production capacity with two additional production units for its CDMO business to be commissioned in FY 2025. Some of its production facilities have been accredited by various global regulatory bodies such as the European Good Manufacturing Practice (EU-GMP), the World Health Organization Good Manufacturing Practice (WHO-GMP) and the United States National Sanitation Foundation (US NSF).
As of September 30, 2023, Akums Drugs and Pharmaceuticals had a total of 16,463 employees, including 7,211 full-time employees and 9,252 contract employees.
Akums Drugs and Pharmaceuticals Limited IPO Analysis
Akums Drugs and Pharmaceuticals Limited is set to launch its Initial Public Offering (IPO), offering investors a chance to be a part of a leading player in the pharmaceutical manufacturing sector. Here’s a detailed analysis of the IPO, highlighting its key aspects, pros, and cons.
Key Details of Akums Drugs and Pharmaceuticals Limited IPO
Company Overview: Akums Drugs and Pharmaceuticals Limited, incorporated in 2004, has established itself as a prominent name in the pharmaceutical manufacturing industry. With its registered office in Delhi and corporate office in Mangolpuri Industrial Area, Delhi, the company has built a robust market presence.
Promoters: The company’s promoters are Sanjeev Jain, Sandeep Jain, and Akums Master Trust, all of whom bring extensive experience and strategic vision to the organization.
IPO Structure:
- Fresh Issue: Up to ?6,800 million.
- Offer for Sale: Up to 17,330,435 equity shares.
Book Running Lead Managers: The IPO is managed by reputed firms including ICICI Securities Limited, Axis Capital Limited, Citigroup Global Markets India Private Limited, and Ambit Private Limited.
Registrar to the Offer: Link Intime India Private Limited will handle the registrar responsibilities for the IPO.
Pros of Investing in Akums Drugs and Pharmaceuticals Limited IPO
- Established Market Presence: Akums has a strong foothold in the pharmaceutical manufacturing sector.
- Diverse Product Portfolio: The company’s wide range of products caters to various market needs, ensuring a broad customer base.
- Experienced Management Team: Led by seasoned professionals, the management team has a proven track record in the industry.
- Strategic Partnerships: Collaborations with key industry players enhance the company’s market position.
- Strong Financial Performance: Consistent revenue growth and profitability reflect the company’s robust financial health.
Cons of Investing in Akums Drugs and Pharmaceuticals Limited IPO
- Regulatory Risks: The pharmaceutical industry is subject to stringent regulations, which can impact the company’s operations.
- Competition: The market is highly competitive, requiring continuous innovation and investment to maintain market share.
- Dependence on Key Customers: A significant portion of revenue is derived from a few key customers, posing a risk to revenue stability.
- Market Risks: Stock market fluctuations can affect the company’s post-IPO performance.
- Operational Risks: Disruptions in manufacturing processes can impact product supply and revenue.
Conclusion
The Akums Drugs and Pharmaceuticals Limited IPO presents a promising investment opportunity, backed by the company’s strong market presence, diverse product portfolio, and experienced management team. However, potential investors should carefully consider the regulatory, market, and operational risks associated with the pharmaceutical industry before making an investment decision.
FAQs About Akums Drugs And Pharmaceuticals Limited Ipo
Akums Drugs and Pharmaceuticals Limited IPO will open on 30 Jul, 2024 and close on 01 Aug, 2024. Investors must apply within this period to participate.
The Akums Drugs and Pharmaceuticals Limited IPO price band is set between ₹646.00 and ₹679.00 per share. The minimum lot size is 22, requiring an investment of at least ₹14938.00.
The Akums Drugs and Pharmaceuticals Limited IPO shares are expected to be listed on 06 Aug, 2024, subject to regulatory approvals and final allotment.
You can track your Akums Drugs and Pharmaceuticals Limited IPO application status on the registrar’s website: Link Intime or KFintech using your PAN, application number, or DP ID
The Akums Drugs and Pharmaceuticals Limited IPO will be listed on major stock exchanges such as BSE, where you can trade shares once they are listed.